Selected article for: "HDV Hepatitis delta virus and Hepatitis delta virus"

Author: Li, Wenhui; Urban, Stephan
Title: Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications
  • Cord-id: qx8emdlr
  • Document date: 2016_4_12
  • ID: qx8emdlr
    Snippet: For almost three decades following the discovery of the human Hepatitis B Virus (HBV) the early events of virus infection (attachment to hepatocytes, specific binding to a receptor on hepatocytes) remained enigmatic. The gradual improvement of tissue culture systems for HBV has enabled the identification of viral determinants for viral infectivity and facilitated the discovery of the human sodium taurocholate co-transporting polypeptide (hNTCP) as a liver specific receptor of HBV and its satelli
    Document: For almost three decades following the discovery of the human Hepatitis B Virus (HBV) the early events of virus infection (attachment to hepatocytes, specific binding to a receptor on hepatocytes) remained enigmatic. The gradual improvement of tissue culture systems for HBV has enabled the identification of viral determinants for viral infectivity and facilitated the discovery of the human sodium taurocholate co-transporting polypeptide (hNTCP) as a liver specific receptor of HBV and its satellite, the human Hepatitis Delta Virus (HDV). These findings are currently leading basic and clinical research activities in new directions. (1) Stable hNTCP-expressing cell lines have become a valuable platform to study the full HBV replication cycle from its native template, the cccDNA. (2) The suitability of NTCP complemented cell culture systems for high throughput screening approaches will facilitate identification of novel host factors involved in HBV replication (including those that determine the peculiar host specificity of HBV infection) and will enable identification and development of novel drug candidates for improved therapeutics. (3) Since NTCP is a major host-specific restriction factor for HBV and HDV, hNTCP-expressing animals provide the basis for future susceptible in vivo models. (4) The concept obtained with the entry inhibitor Myrcludex B demonstrates that NTCP is a suitable target for clinical interference with viral entry. This will foster further clinical approaches aiming at curative combination therapies.

    Search related documents:
    Co phrase search for related documents
    • action mode and liver cancer: 1, 2
    • action mode and liver cancer cell: 1, 2
    • action mode and liver cell: 1, 2
    • action mode and low concentration: 1
    • acute infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and liver biopsy: 1, 2, 3, 4, 5, 6
    • acute infection and liver biopsy immunohistochemistry: 1
    • acute infection and liver cancer: 1, 2, 3, 4, 5, 6, 7, 8
    • acute infection and liver cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute infection and liver specific: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute infection and liver study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute infection and liver study european association: 1
    • acute infection and liver transplant: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute infection and long term consequence: 1
    • acute infection and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • liver cancer and long term administration: 1